WASHINGTON — A closely watchedwon the backing of federal health advisers on Monday, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease.
“I thought the evidence was very strong in the trial showing the effectiveness of the drug,” said panel member Dean Follmann, a National Institutes of Health statistician. At a high level, Lilly’s results mirrored those of Leqembi, with both medications showing a modest slowing of cognitive problems in patients with early-stage Alzheimer’s. The Indianapolis-based company conducted a 1,700-patient study showing patients who received monthly IV infusions of its drug declined about 35% more slowly than those who got a sham treatment.
In another key difference, Lilly studied taking patients off its drug when they reached very low levels of amyloid, a sticky brain plaque that's a contributor to Alzheimer's.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Unilab lauds FDA’s proactive measures vs fake drugsPharmaceutical and healthcare company Unilab Inc. lauded the Food and Drug Administration (FDA) for taking proactive measures to protect the public from the perils of purchasing fake medicines.
Source: PhilstarNews - 🏆 1. / 94 Read more »